Navigation Links
New research shows ACTOS is associated with a 38 percent lower risk of heart attack
Date:9/22/2007

Amsterdam, The Netherlands, Sept. 19, 2007 -- New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS (pioglitazone HCI) and its benefits regarding improved blood glucose and blood lipid levels for patients with type 2 diabetes. The unique outcomes, including some clinical practice results, reinforce the consistency of pioglitazone data and underscore that ACTOS has different effects from the other thiazolidinedione rosiglitazone due to differences in molecular structure.

New research [1] presented at EASD has shown that therapies which include pioglitazone are associated with significant reductions in the risk of stroke or myocardial infarction (MI) compared to non-thiazolidinedione therapies. This retrospective analysis of case records from a large managed care database of diabetes patients have shown that the adjusted relative risk of stroke for the pioglitazone group was 20 percent lower than the group not receiving pioglitazone. Likewise, the risk of heart attack over the study period was 38 percent lower in patients receiving pioglitazone than in those taking an anti-diabetes drug regimen that did not include pioglitazone. John Betteridge, Professor of Endocrinology and Metabolism at University College, London said: The results of this analysis are very welcome and support the findings from the PROactive study of pioglitazone for secondary prevention of vascular events which showed a reduction in stroke and heart attack in this high risk population.

In addition, the GLAI study [2] , also presented at EASD, further reflects the cardioprotective strength of pioglitazone. A new analysis of data from the first three months of this six-month head-to-head study of pioglitazone and rosiglitazone, in which the endpoint was the change in serum lipids, demonstrated that initial treatment with a starting dos
'/>"/>

Contact: Alison Wright
alison.wright@ketchum.com
44-207-611-3662
Ketchum
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Stem cell research- now Nobel Laureates join the debate
3. Researchers urge caution in using ear tube surgery
4. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
5. Spouses and other partners lower blood pressure says new research
6. Researchers Scale to assess the Severity of Epilepsy in Kids
7. More Research Required For COPD
8. Researchers identify the early makers of Neonatal Sepsis
9. OHSU Researchers Announce New Discovery
10. Skin Cancer Research To Go Global
11. Researchers Identify Gene Connected To Bipolar Disorder

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Recent Reviews In Major Peer Review Jo...t Promising New Developments For The Evidence-Base...g Difficulties. Some Of The Most Recent Are Listed...r 1, 2009 -- Review written by: Leesa V. Huang Ph....e 13, No. 3 November 2009. A nice synopsis of this...
(Date:12/1/2009)... Anthony M. Marlon, MD was elected to t...dica”) Board of Directors at the Company&rsq... (PRWEB) December 1, 2009 -- Anthony M. ...nologies , Inc. (“Stemedica”) Board of...ard Meeting. Roger J. Howe, PhD, Executive Chairma...
(Date:12/1/2009)... All Federal and Georgia State Retirees...nefits. This new benefit is part of the Medicare A...ivate fee for service (PFFS) Options offered by CI... Kaiser Permanente. Atlanta Hearing Associates has...A Lake Oconee / Greensboro, GA and Lake Sinclair /...
(Date:12/1/2009)...GAN, Minn., Dec. 1 "The patient wi...h care for Blue Cross and Blue Shield of Minnesota...ming the first Minnesotans - and the first in the ...nywhere(SM). Online Care Anywhere allows patients ... logging onto a computer or picking up the phone. ...
(Date:12/1/2009)..., SEATTLE, Dec. 1 Cel...management,s presentation at the 21st Annual Piper...er 1 at 11:00 a.m. Eastern Time will be webcast li...entation will take place in Holmes 1 at the New Yo...play after the presentation. , , ...
Breaking Medicine News(10 mins):Health News:Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV 2Health News:Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV 3Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 2Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 3Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 2Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 3Health News:Retired Fed. & GA State Employees Get New Hearing Healthcare Benefit, Jan. 2010 4Health News:Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM) 2Health News:Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM) 3
...ional diabetes study of more than 52,000 patients ... BIAsp 30 insulin resulted in significant clinical... The findings, reported in the March issue of IJC...get set by the International Diabetes Foundation. ...
... Most Health Plan Members Drop Coverage for...nd Senior Management Commitment Are Necessary,to R... Orlando, FL (Vocus) March ...perly managing member disenrollment delivers a sig...
...March 2 Building on a proven track record of succ...e B. Richman today announced the U.S. Department o...eving a 75 percent participation rate in the Suppl... USDA once again for our efforts to ensure the bas...
...h 2 /PRNewswire-Asia/ -- Himfr.com,( http://www.h...B2B search,platforms with more than 30 B2B industr...oods to eat in spring. , Cherry: , Cherry ...w.himfr.com/buy-apple/ ), pear ( http://www.himf...
...orld Health Care Congress will feature the nation,...issues ranging from the impact of health reform un...nd practices that are shaping the delivery of care... for the most recent insights on health. , WHAT: ...
...arch 2 Herley Industries, Inc. (Nasdaq: HRLY ) ... has received contract awards totaling approximate...ufacture of complex integrated microwave assemblie...ts for use in the APG-68 radar system on various U...
Other Medicine News:Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 2Health News:Insulin drug study shows significant improvements in more than 52,000 diabetic patients 3Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 3Health News:Himfr.com Recommends Five Foods for Spring 2Health News:World Health Care Congress to convene preeminent leaders for 3 days on rebuilding health care 2Health News:Herley Lancaster Awarded $1.0 Million in New Contracts 2
(Date:11/30/2009)...C., Nov. 30 Microban International...l product protection, is pleased to announce their... Corp., the largest U.S. manufacturer and distribu...orp is launching two new lines of ceramic tile wit...;) patent pending silver based technology, in orde...
(Date:11/30/2009)...PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI... technique for the detection of ductal carcinoma i...er. BSGI is a molecular breast imaging technique t...and discover very early stage cancers. According t...f the Radiological Society of North America (RSNA)...
(Date:11/30/2009)..., Nov. 30 SCOLR Pharma, ...vember 25, 2009, the NYSE Amex LLC (the "Exchange"...mpany,s plan to comply with its previously disclos... the Exchange Company Guide. Specifically, the de...losses which were so substantial in relation to it...
Breaking Medicine Technology:Dal-Tile Corp. Launches Two New Lines of Ceramic Tile with Microban(R) Silver Antimicrobial Technology 2Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4University of Louisville neuroscientists hope to get people walking again 58667 1Experts gather at McGill University to address food security challenges 10216 1EPA reviews Univ of Michigan dioxin study 10212 1EPA reviews Univ of Michigan dioxin study 10212 2
... EnVivo Pharmaceuticals, Inc.,a privately held bio...egenerative diseases, today announced progress on ...chizophrenia and Huntington,s,diseases. EnVivo Ph...orally,active Alpha 7 Nicotinic Acetylcholine Rece...ts associated with Alzheimer,s disease and,Schizop...
...h Joint Venture Between Bristol-Myers Squibb, Co...n HIV Treatment -, PRINCETON, N.J. and FOSTER CIT...ol-Myers Squibb Company (NYSE: BMY ) and Gilead S...t Health Canada has approved ATRIPLA(R),(efavirenz...fumarate 300,mg) for the treatment of HIV-1 infect...
Other Medicine Technology:EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 2Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 3Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 4Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 5Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 6Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 7Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 8Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV 9
.../See™ is a 1-step, hand-held, point-of-care ...ug metabolites in human urine. The TOX/See device... drugs in 3 to 8 minutes and requires only a few d...ly packaged to maximize convenience and ease of us...
ESR-10 Manual Rack
...eck Cytometry Concentrate is for use as a sheath f...ach 70ml bottle of Cytometry Concentrate dilutes t...d to Cubitainers, Streck Cytometry Concentrate red...es money without compromising performance. Streck ...
CD-Chex CD34 Leukocyte Control
Medicine Products: